Institution view

Tianjin Medical University Cancer Institute and Hospital

Programs currently tracked for this institution in the public Translational Deal Radar dataset.

Car Nk

Selinexor

Selinexor is flagged as a platform signal because it has an active early-phase oncology cell-therapy trial at Tianjin Medical University Cancer Institute and Hospital, with a possible patent signal linked through modality_match. Manual review is still required.

Phase2 · Not Yet Recruiting

View asset